[Empiric therapy with @entity3400 plus @entity4509 for febrile XXXX with @entity5 --with emphasis on @entity3028 ].

@entity1 @entity4005 @entity796 @entity1910 @entity5 @entity5609 @entity4509 @entity281 @entity3400 @entity3028 @entity221 @entity526 @entity2259
Between August 1979 and December 1983 one hundred episodes of @entity221 in 70 @entity1 with @entity5 , most of whom had @entity3028 , were treated empirically with a combination of @entity3400 (4.0g, every 6 hours) and @entity4509 (200mg, every 6 hours) at Saitama @entity5 Center. Profound @entity3028 (less than 100/mm3 of granulocytes) was present at the beginning of treatment in 40% of episodes. Oral absorbable or nonabsorbable antibiotics were used in 57 febrile episodes. WBC transfusion was not given. The response rate for all documented @entity281 was 58.1%, including 8 of 9 (88.8%) episodes of @entity2259 . The majority of @entity281 with identified organisms were caused by aerobic gram-negative pathogens including @entity796 (8 cases), @entity4005 spp. (3 cases), @entity526 (4 cases), @entity5609 (2 cases) and serratia spp. (3 cases). The response rate of gram-negative @entity281 was 55% Pneumonia with a response rate of 21.1% responded less satisfactorily than all other types of @entity281 . The response rate for profound persistent @entity3028 (less than 100/mm3 granulocytes without a rise during therapy) was 45.5%. The most common adverse effect was hepatotoxicity (16 episodes). Nephrotoxicity occurred in 4 @entity1 and @entity1910 in 2 @entity1 .
